The U.S. Food and Drug Administration (FDA) recently approved PERSERIS, Indivior’s subcutaneous (applied under the skin), long-acting injectable for the treatment of schizophrenia. While the drug achieved clinically relevant levels after its first injection, PERSERIS is not intended to serve as a preventive vaccine.
Contained in PERSERIS is risperidone, an antipsychotic medication known for its efficacy in treating schizophrenia, bipolar disorder, and irritability in individuals with autism. The treatment is a once-monthly injection, meaning that it provides sustained levels of risperidone over the entirety of a month. The drug’s trial included a phase 3 randomized, double-blind, placebo-controlled, 8-week study of 354 participants.
Indivior is a specialty pharmaceuticals business. The company’s main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.
This was reported by Precision Vaccinations on July 31, 2018.
Contact Information: Indivior Inc., 10710 Midlothian Turnpike, North Chesterfield, Virginia 23235; (804) 379-1090; Website: www.indivior.com